Drugs / Ulixertinib
Trials 18 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05804227 | Apr 2023 → Sep 2027 expected | glioma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT05985954 | Jan 2024 → Mar 2028 expected | colorectal cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04145297 | Mar 2020 → Jun 2022 | digestive system neoplasm | University of Utah | Completed | No outcome recorded |
| Phase 1 | NCT03454035 | Jan 2018 → Jul 2026 overdue | malignant pancreatic neoplasm, melanoma | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT02994732 | Jan → Feb 2017 | — | BioMed Valley Discoveries, Inc | Completed | No outcome recorded |
| Phase 1 | NCT02608229 | Jun 2016 → Mar 2019 | malignant pancreatic neoplasm | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06773195 | Jan 2025 → Jan 2028 expected | myelofibrosis | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02296242 | Nov 2014 → Jun 2017 | acute myeloid leukemia, myelodysplastic syndrome | BioMed Valley Discoveries, Inc | Completed | No outcome recorded |
| Phase 1/2 | NCT01781429 | Mar 2013 → Feb 2018 | cancer | BioMed Valley Discoveries, Inc | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT06411821 | May 2024 → May 2027 expected | histiocytic and dendritic cell neoplasm | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05221320 | May 2022 → May 2024 | digestive system cancer, soft tissue neoplasm | BioMed Valley Discoveries, Inc | Terminated | No outcome recorded |
| Phase 2 | NCT04488003 | Jan 2021 → Feb 2023 | neoplasm | BioMed Valley Discoveries, Inc | Terminated | No outcome recorded |
| Phase 2 | NCT06400225 | Jul 2019 → Dec 2026 expected | plasma cell myeloma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03698994 | Nov 2018 → Mar 2022 overdue | Ewing sarcoma, Langerhans cell histiocytosis, Wilms tumor, bone osteosarcoma +12 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03417739 | Mar 2018 → May 2020 | uveal melanoma | Dana-Farber Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT03155620 | Jul 2017 → Mar 2025 overdue | Ewing sarcoma, Langerhans cell histiocytosis, Wilms tumor, conventional osteosarcoma +13 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02465060 | Aug 2015 → Dec 2026 expected | breast carcinoma, carcinoma of esophagus, cervical carcinoma, colon carcinoma +17 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04566393 | — | cholangiocarcinoma, colorectal cancer, esophageal cancer, gastric cancer +10 | xCures | Available | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ulixertinib | “Here we report the discovery of BVD-523 (ulixertinib), a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity.” PMID 28939558 ↗ Sep 2017 |
| Known as | BVD-523 | “Ulixertinib (BVD-523) is an oral, first-in-class ERK1/2 inhibitor” NCT04566393 ↗6“Ulixertinib (BVD-523)” NCT06411821 ↗ |
| Known as | BVD-ERK | ChEMBL registry synonym — accepted as the source's own label CHEMBL3590106 ↗ |
| Known as | ULIXERTINIB (BVD-523) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3590106 ↗ |
| Known as | VRT-752271 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3590106 ↗ |
| Action | Inhibit | “Here we report the discovery of BVD-523 (ulixertinib), a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity.” PMID 28939558 ↗ Sep 2017 |
| Modality | Small molecule | “Here we report the discovery of BVD-523 (ulixertinib), a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity.” PMID 28939558 ↗ Sep 2017 |
| Route | Oral | “Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle” NCT01781429 ↗ |
| Target | MAPK1 | “MAP kinase ERK2 inhibitor” CHEMBL3590106 ↗ |
| Target | MAPK3 | “MAP kinase ERK1 inhibitor” CHEMBL3590106 ↗ |